Navigation Links
Possible predictive biomarker for patients who may respond to autophagy inhibitors
Date:4/8/2013

WASHINGTON, DC Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy.

A team led by researchers from the Perelman School of Medicine at the University of Pennsylvania will present findings (Presentation #1679A) during the AACR Annual Meeting 2013 showing that colon cancer and lung cancer cell lines which expressed a gene known as helicase-like transcription factor (HLTF) tended to be impervious to the effects of the autophagy inhibition drug hydroxycholoroquine (HCQ), a drug originally used as an antimalarial agent. Cells where HLTF is silent, however, appeared to be sensitive to HCQ, which led the team to test HLTF expression in a group of colon cancer patients treated with two chemotherapies (the FOLFOX regimen plus bevacizumab) and HCQ. They found that low expression of HLTF predicted those who would respond to the combination therapy.

Since previous studies have shown that HLTF gene silencing is common in 20 to 40 percent of many epithelial cancers, the Penn team is hopeful their findings could lead to the development of a predictive biomarker to identify patients with other cancers who are most likely to respond to drug therapies involving autophagy inhibitors.

The study will be presented by Ravi Amaravadi, MD, in the Autophagy and Cell Death poster session, Hall A-C, Poster Section 23, at the at the Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, DC 20001, from 1 p.m. to 5 p.m. ET on Monday, April 8, 2013.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. Causes of migraines nearly impossible to determine
2. Early COPD diagnosis possible with nuclear medicine
3. Mesothelioma Victims Center Now Urges Any Retired Industrial or Manufacturing Worker Diagnosed With Mesothelioma To Call Them For The Names Of The Best Possible Law Firms
4. Lung Cancer Asbestos Victims Center Now Urges All Industrial Workers Who Had Exposure to Asbestos at Work and Now Have Lung Cancer to Call Them About Possible Compensation
5. Lung Cancer Asbestos Victims Center Now Urges Nonsmoker US Navy Veterans Who Have Any Type Of Lung Cancer To Call them About Possible Compensation
6. Mesothelioma Victims Center Now Urges All Diagnosed Victims Of Mesothelioma To Call Them Immediately For The Names Of The Best Possible Mesothelioma Law Firms
7. Lung Cancer Asbestos Victims Center Urges US Navy Veterans Stricken With Any Type Of Lung Cancer If They Were Exposed In Asbestos - Possible Significant Compensation
8. Los Angeles Periodontist, Dr. Markzar, is Now Informing Patients about the Possible Connection between Gum Disease and Cardiovascular Disease
9. Lung Cancer Asbestos Victims Center Urges Nonsmokers Now Diagnosed With Lung Cancer To Call Them If They Were Exposed To Asbestos At Work-Possible Financial Compensation
10. Lung Cancer Asbestos Victims Center Now Urges US Navy Veterans Who Now Have Lung Cancer And Were Exposed To Asbestos To Call Them About Possible Financial Compensation
11. Mesothelioma Victims Center Now Urges All Victims Of Mesothelioma To Call Them About Financial Compensation And For The Names Of The Best Possible Mesothelioma Law Firms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing ... by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the ... 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: